[Helicobacter pylori eradication therapy in Korea]

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Helicobacter pylori (H. pylori) infection is linked to various gastrointestinal conditions, including peptic ulcers.
• H. pylori eradication is a clinical recommendation in Korea for peptic ulcer disease, gastric MALT lymphoma, and early gastric cancer.

Purpose of the Study:

• To review current H. pylori eradication therapies in Korea.
• To highlight the declining efficacy of standard triple therapy due to antimicrobial resistance.
• To discuss alternative and emerging treatment options for H. pylori.

Main Methods:

• Review of established first-line and second-line H. pylori eradication regimens in Korea.
• Analysis of treatment success rates in relation to antimicrobial resistance patterns.
• Exploration of third-line and novel therapeutic approaches.

Main Results:

• Standard triple therapy (proton pump inhibitor, clarithromycin, amoxicillin) and bismuth-containing quadruple therapy are primary treatments.
• Eradication rates for second-line quadruple therapy remain stable, but triple therapy success has decreased.
• Increasing antimicrobial resistance is a significant factor in reduced H. pylori eradication rates with triple therapy.

Conclusions:

• The efficacy of standard H. pylori triple therapy is compromised by rising antimicrobial resistance.
• There is no standardized third-line therapy, with options including levofloxacin, moxifloxacin, and rifabutin.
• Novel regimens like sequential and concomitant therapies are proposed, necessitating further randomized controlled trials for optimal H. pylori treatment selection.